I went looking to get current on the state of sorafenib therapy and found a good read I'd like to recommend to all. Published online in the World Journal of Hepatology, 7/27/13:
"Mechanisms of Resistance to Sorafenib and the corresponding strategies in HCC"
Good piece on current state of research toward mediating sorafenib resistance, with good analysis of the P2 results of high-MET, 2nd line HCC, tivantinib-treated patient pops. Might provide a good preview of the analytics we might find in Cabo's post- Nexavar "Celestial" trial that should be recruiting next month, and I think will be discussed at length at the coming ER. Good informative read for those looking to understand the strategy of Cabo's pending P3 trial. Commentary invited...